Everyone talks about safety, everyone will respond to emergencies, and all enterprises will earnestly implement the "Safety Month" activities.
Release time:
2023-06-12
5# On March 26, the pharmaceutical company took the lead in holding the start-up meeting of the safety production month to convey the overall plan of the group company's "safety production month" activities and implement the various activities of the pharmaceutical company's safety month. Huang Jinlong, deputy general manager of the group company and general manager of the pharmaceutical company, emphasized that safety work should not stay on the surface. Through safety month activities, the safety awareness of all employees should be improved, improved, and changed, and the problems found in the inspection should be strict. Deal with it and effectively improve the level of safety management. On May 30 and June 1, Anhui Jianfeng North Carolina and Tianjin Jianfeng Natural Products Co., Ltd. successively held the launching ceremony of "Safety Production Month". According to the activity plan, the division of tasks was clarified, and supervision, inspection and assessment were implemented to ensure that the activities achieved comprehensive improvement of intrinsic safety. Level, promote the continuous improvement of the safety production situation. On June 1,
6#, the three cement enterprises held the launching ceremony of "safe production month". in addition to conveying the relevant requirements of the group company and implementing the activity plan of the enterprise, they also adopted the form of signature commitment. cadres and employees signed their names on the banners and publicity boards of "safe production month" and solemnly made a commitment to safe production.
Peak Health, cable companies and other enterprises have also held special meetings to implement the work of "safe production month.
Since the launch of the group company's "safe production month" activity plan in mid-May, all enterprises have actively carried out various publicity, training, job safety hazard investigation and management activities in various production enterprises in the form of playing videos of safe production and typical cases, putting up publicity posters and slogans, and setting up safety knowledge display boards. The 2023 Edition of Safety Accident Case Data has been compiled and compiled by the Safety Management Office of the Group. From the typical industry cases compiled and reported by various enterprises, 15 accident cases of chemical enterprises, 20 accident cases of cement enterprises and 15 accident cases of general industrial and trade enterprises have been selected and distributed to all enterprises for organizational study after being compiled into a book."Safety Production Month" is a normalized and institutionalized activity carried out nationwide, aiming to enhance the safety awareness and independent security capabilities of the whole society. Tao Yecheng, deputy general manager of Daye Peak, believes that the "Safety Production Month" activity is only a form and opportunity. The goal is to improve employees' safety awareness and improve the safety production level of enterprises. To achieve this, we must strive to achieve the normalization of safety publicity and education. And the sustainability of safety culture construction, combining the three-year on-site governance action plan with the group company's safety work guiding ideology, and carrying out safety activities based on the actual work, promote the company's safety production situation continues to be stable, and strive to achieve the goal of "building a safe factory, happy factory. (Lu Xianhui, Song Danlin, Hu Ning, Cai Chengbing, Li Li, Liu Fengbin)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page